I agree with you except for the first sentence. As I have been told, the DSMB can stop the trial for safety or futility consideration. The company stops the trial if it believes, based on the DSMB report, it has achieved sufficient efficacy to submit the results to the FDA. At that time, the company can see the results and complete the analysis.